Skip to content

S. 1906 · 118th Congress (2023–2025)

Promising Pathway Act

This bill provides for expedited, provisional approval of drugs for serious or life-threatening diseases or conditions.

Specifically, the bill allows for provisional approval of drugs that are used to treat, prevent, or diagnose a serious or life-threatening disease or condition for which premature death is likely without early medical intervention. The Food and Drug Administration (FDA) must evaluate applications within 90 days of receipt. The FDA may approve applications if there is early evidence, including real-world and real-time evidence, of the drug's efficacy, as well as substantial evidence of the drug's safety. Provisional approval is valid for two years and may be renewed for up to eight years. The FDA may withdraw provisional approval in the event of serious adverse health effects.

Drug sponsors that receive provisional approval must require all patients receiving the drug to participate in an observational registry, through which the drug sponsor may collect and submit data relating to the drug until it is fully approved. Registries may be operated by the drug sponsor or another entity. The FDA must annually review these registries; sponsors of registries that fail to meet the bill's requirements are subject to civil penalties.

Show official title

A bill to amend the Federal Food, Drug, and Cosmetic Act to establish a time-limited provisional approval pathway, subject to specific obligations, for certain drugs and biological products, and for other purposes.

Expired in Senate committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to committee

This bill’s path

This is S. 1906’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed Senate

  3. Passed House

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Sen. Mike Braun (R-IN)
Cosponsors
19 cosponsors

4 original · 15 later

11 R · 8 D

  1. Sen. Kevin Cramer (R-ND)· Original · Jun 8, 2023
  2. Sen. Kirsten E. Gillibrand (D-NY)· Original · Jun 8, 2023
  3. Sen. Lisa Murkowski (R-AK)· Original · Jun 8, 2023
  4. Sen. Roger F. Wicker (R-MS)· Original · Jun 8, 2023
  5. Sen. Joe Manchin III (D-WV)· Later · Oct 18, 2023
  6. Sen. Raphael G. Warnock (D-GA)· Later · Oct 24, 2023
  7. Sen. Lindsey Graham (R-SC)· Later · Nov 1, 2023
  8. Sen. Eric Schmitt (R-MO)· Later · Nov 1, 2023
  9. Sen. J. D. Vance (R-OH)· Later · Nov 1, 2023
  10. Sen. Alex Padilla (D-CA)· Later · Nov 2, 2023
  11. Sen. Jeanne Shaheen (D-NH)· Later · Nov 2, 2023
  12. Sen. Steve Daines (R-MT)· Later · Nov 7, 2023
  13. Sen. Cynthia M. Lummis (R-WY)· Later · Nov 7, 2023
  14. Sen. Pete Ricketts (R-NE)· Later · Nov 7, 2023
  15. Sen. Shelley Moore Capito (R-WV)· Later · Nov 8, 2023
  16. Sen. Jon Tester (D-MT)· Later · Nov 14, 2023
  17. Sen. Peter Welch (D-VT)· Later · Dec 7, 2023
  18. Sen. John Fetterman (D-PA)· Later · Dec 12, 2023
  19. Sen. John Kennedy (R-LA)· Later · Jan 10, 2024
Policy area
Health
Subjects
  • Administrative law and regulatory procedures
  • Civil actions and liability
  • Congressional oversight
  • Department of Health and Human Services
  • Drug safety, medical device, and laboratory regulation
  • Health information and medical records
  • Prescription drugs

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in Senate

    Document: Introduced in Senate

    Sources
  2. Latest

    Referred to committee

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Sources
  3. Expired

    Introduced → Referred to Senate Health, Education, Labor, and Pensions → No further action before the 118th Congress ended.

Committees

  1. SenateHealth, Education, Labor, and PensionsReferred Jun 8, 2023

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in Senate
Titles (2)
  1. Promising Pathway Act

    Display title, Short title · Introduced in Senate

  2. A bill to amend the Federal Food, Drug, and Cosmetic Act to establish a time-limited provisional approval pathway, subject to specific obligations, for certain drugs and biological products, and for other purposes.

    Official title · Introduced in Senate